AP848A - 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors. - Google Patents

6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors. Download PDF

Info

Publication number
AP848A
AP848A APAP/P/1997/001156A AP9701156A AP848A AP 848 A AP848 A AP 848A AP 9701156 A AP9701156 A AP 9701156A AP 848 A AP848 A AP 848A
Authority
AP
ARIPO
Prior art keywords
nmr
disease
cdci
mmol
parent
Prior art date
Application number
APAP/P/1997/001156A
Other languages
English (en)
Other versions
AP9701156A0 (en
Inventor
Iii John Adams Lowe
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701156A0 publication Critical patent/AP9701156A0/xx
Application granted granted Critical
Publication of AP848A publication Critical patent/AP848A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1997/001156A 1996-12-06 1997-12-04 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors. AP848A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3279396P 1996-12-06 1996-12-06
PCT/IB1997/001446 WO1998024766A1 (en) 1996-12-06 1997-11-17 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors

Publications (2)

Publication Number Publication Date
AP9701156A0 AP9701156A0 (en) 1998-01-31
AP848A true AP848A (en) 2000-06-09

Family

ID=21866837

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001156A AP848A (en) 1996-12-06 1997-12-04 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors.

Country Status (42)

Country Link
US (3) US6235750B1 (cs)
EP (1) EP0946512B1 (cs)
JP (2) JP3604399B2 (cs)
KR (1) KR100360633B1 (cs)
CN (1) CN1117077C (cs)
AP (1) AP848A (cs)
AR (1) AR010331A1 (cs)
AT (1) ATE251612T1 (cs)
AU (2) AU4791797A (cs)
BG (1) BG103540A (cs)
BR (1) BR9714381A (cs)
CA (1) CA2273479C (cs)
CZ (1) CZ293863B6 (cs)
DE (1) DE69725465T2 (cs)
DK (1) DK0946512T3 (cs)
DZ (1) DZ2361A1 (cs)
EA (1) EA002907B1 (cs)
ES (1) ES2206691T3 (cs)
HN (2) HN1997000027A (cs)
HR (1) HRP970664A2 (cs)
HU (1) HUP0001848A3 (cs)
ID (1) ID19056A (cs)
IL (1) IL130111A0 (cs)
IS (1) IS5053A (cs)
MA (1) MA26453A1 (cs)
NO (1) NO313517B1 (cs)
NZ (1) NZ335733A (cs)
OA (1) OA11123A (cs)
PA (1) PA8442201A1 (cs)
PE (1) PE46499A1 (cs)
PL (1) PL333918A1 (cs)
PT (1) PT946512E (cs)
SI (1) SI0946512T1 (cs)
SK (1) SK70899A3 (cs)
TN (1) TNSN97198A1 (cs)
TR (1) TR199901259T2 (cs)
TW (1) TW491840B (cs)
UA (1) UA59379C2 (cs)
UY (1) UY24799A1 (cs)
WO (1) WO1998024766A1 (cs)
YU (1) YU25399A (cs)
ZA (1) ZA9710906B (cs)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3455229B2 (ja) * 1996-03-29 2003-10-14 ファイザー インク． ６―フェニルピリジル―２―アミン誘導体
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
HN1998000125A (es) * 1997-08-28 1999-02-09 Pfizer Prod Inc 2-aminopiridinas con sustituyentes alcoxi ramificados
NZ508057A (en) 1998-06-03 2003-07-25 Pfizer Prod Inc 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors
FR2791674A1 (fr) * 1999-04-02 2000-10-06 Sod Conseils Rech Applic Nouveaux derives de 2-aminopyridines, leur utilisation en tant que medicaments et compositions pharmaceutiques les contenant
FR2780971B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Nouveaux derives de 2-aminopyridines, leur application en tant que medicaments et compositions pharmaceutiques les contenant
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
AP2001002067A0 (en) * 1998-08-11 2001-03-31 Pfizer Prod Inc New pharmaceutical uses for nos inhibitors.
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
ES2200813T3 (es) 1999-02-25 2004-03-16 Pfizer Products Inc. 2-aminopiridinas que contienen sustituyentes de anillo condesado.
HK1046645A1 (zh) * 1999-07-23 2003-01-24 盐野义制药株式会社 Th2分化抑制剂
FR2804429B1 (fr) * 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002080853A2 (en) * 2001-04-09 2002-10-17 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
CA2522323C (en) * 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
CN1295216C (zh) * 2003-07-04 2007-01-17 中国人民解放军军事医学科学院毒物药物研究所 吲哚酮类衍生物及其用于制备抗肿瘤药物的用途
US20080070952A1 (en) * 2005-02-21 2008-03-20 Proximagen Ltd., Inhibition or Treatment of Dyskinesia
WO2006105795A1 (en) * 2005-04-08 2006-10-12 Leo Pharma A/S Novel indolinone derivatives
WO2008021849A2 (en) * 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
EP2152270B1 (en) 2007-06-08 2015-03-04 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
EP2152269B1 (en) 2007-06-08 2014-04-23 Janssen Pharmaceutica, N.V. Piperidine/piperazine derivatives
CA2725933C (en) 2008-06-05 2018-01-16 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US8889674B2 (en) * 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
US11013844B2 (en) * 2014-11-20 2021-05-25 City Of Hope Treatment device for plasma virus inactivation
TWI874960B (zh) 2016-08-12 2025-03-01 美商亞瑟尼克斯公司 聯芳組成物和調控激酶級聯之方法
PT3684767T (pt) 2017-09-22 2024-07-29 Jubilant Epipad LLC Compostos heterocíclicos como inibidores de pad
ES2941512T3 (es) 2017-10-18 2023-05-23 Jubilant Epipad LLC Compuestos de imidazo-piridina como inhibidores de PAD
SG11202004143XA (en) 2017-11-06 2020-06-29 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
KR102780935B1 (ko) 2017-11-24 2025-03-12 주빌런트 에피스크라이브 엘엘씨 Prmt5 억제제로서의 헤테로사이클릭 화합물
JP7279063B6 (ja) 2018-03-13 2024-02-15 ジュビラント プローデル エルエルシー Ｐｄ１／ｐｄ－ｌ１相互作用／活性化の阻害剤としての二環式化合物
CN114206843A (zh) * 2019-06-14 2022-03-18 Srx心脏有限责任公司 用于调节前蛋白转化酶枯草杆菌蛋白酶/Kexin 9型(PCSK9)的化合物
US12115154B2 (en) * 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014780A1 (en) 1991-02-19 1992-09-03 Akzo N.V. Stabilized carbon monoxide-olefin copolymers
EP0674627A1 (en) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5621004A (en) 1994-06-03 1997-04-15 Robert W. Dunn Method for treating emesis
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JP3455229B2 (ja) * 1996-03-29 2003-10-14 ファイザー インク． ６―フェニルピリジル―２―アミン誘導体
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONE *

Also Published As

Publication number Publication date
UA59379C2 (uk) 2003-09-15
DE69725465T2 (de) 2004-05-06
IL130111A0 (en) 2000-06-01
BR9714381A (pt) 2000-05-02
WO1998024766A1 (en) 1998-06-11
JP3604399B2 (ja) 2004-12-22
PA8442201A1 (es) 2000-05-24
TNSN97198A1 (fr) 2005-03-15
ID19056A (id) 1998-06-11
US20020032191A1 (en) 2002-03-14
CN1117077C (zh) 2003-08-06
AU4791797A (en) 1998-06-29
TR199901259T2 (xx) 1999-08-23
EA199900448A1 (ru) 2000-02-28
BG103540A (bg) 2000-12-29
DE69725465D1 (de) 2003-11-13
ATE251612T1 (de) 2003-10-15
HRP970664A2 (en) 1998-10-31
AU7205001A (en) 2001-11-15
HN1997000149A (es) 1997-12-26
EP0946512B1 (en) 2003-10-08
NO313517B1 (no) 2002-10-14
HUP0001848A3 (en) 2002-03-28
PE46499A1 (es) 1999-05-12
US20020103227A1 (en) 2002-08-01
MA26453A1 (fr) 2004-12-20
NZ335733A (en) 2001-01-26
CZ201799A3 (cs) 2000-07-12
CA2273479A1 (en) 1998-06-11
UY24799A1 (es) 2001-08-27
HUP0001848A2 (hu) 2001-04-28
SK70899A3 (en) 2002-04-04
ES2206691T3 (es) 2004-05-16
JP2000505814A (ja) 2000-05-16
US6235750B1 (en) 2001-05-22
DZ2361A1 (fr) 2002-12-28
KR20000057413A (ko) 2000-09-15
YU25399A (sh) 2001-07-10
JP2005170924A (ja) 2005-06-30
CN1239952A (zh) 1999-12-29
TW491840B (en) 2002-06-21
KR100360633B1 (ko) 2002-11-13
EP0946512A1 (en) 1999-10-06
SI0946512T1 (en) 2004-04-30
AP9701156A0 (en) 1998-01-31
CZ293863B6 (cs) 2004-08-18
DK0946512T3 (da) 2004-01-12
PL333918A1 (en) 2000-01-31
EA002907B1 (ru) 2002-10-31
IS5053A (is) 1999-05-18
AR010331A1 (es) 2000-06-07
HN1997000027A (es) 1997-06-05
ZA9710906B (en) 1999-06-09
CA2273479C (en) 2006-02-07
OA11123A (en) 2003-04-07
PT946512E (pt) 2004-01-30
AU766080B2 (en) 2003-10-09
NO992725D0 (no) 1999-06-04
NO992725L (no) 1999-06-04

Similar Documents

Publication Publication Date Title
AP848A (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors.
CA2890981A1 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
JP2007008816A (ja) 新規イソキノリン誘導体
WO1995028387A1 (en) Benzamide compound and medicinal use thereof
TW200526620A (en) Pyrazine derivatives and pharmaceutical use thereof
TW200536545A (en) Pyrazine derivatives and pharmaceutical use thereof
KR101268890B1 (ko) 메타니코틴 화합물의 하이드록시벤조에이트 염
AU4876900A (en) New beta-carboline compounds a process for their preparation and pharmaceutical compositions containing them
US10112945B2 (en) Fused quinoline compunds as PI3K, mTOR inhibitors
TW201038554A (en) Nicotinamide derivatives, their preparation and their therapeutic application
CN111278814B (zh) 作为毒蕈碱m1受体正向别构调节剂的多环酰胺
JP2501298B2 (ja) モルフアナン類のｏ−アリ―ルエ―テル
US10730878B2 (en) Fused quinoline compounds as PI3K/mTOR inhibitors
CN113891879B (zh) 3,6-二取代的-2-吡啶醛肟骨架
FR2593818A1 (fr) Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
SK17122002A3 (sk) Derivát heterocyklického aminoalkylpyridínu ako psychofarmaceutické činidlo, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
JP3444495B2 (ja) 酸化窒素合成酵素阻害剤として縮合環置換基を含有する２−アミノピリジン
CN116601153A (zh) 作为nav1.8抑制剂的含氮2,3-二氢喹唑啉酮化合物
JP2011508758A (ja) Ｎ−フェニルイミダゾ［１，２−α］ピリジン−２−カルボキサミド誘導体、これらの調製およびこれらの治療用途
US20040142924A1 (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
WO2010109123A1 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
WO2024166024A1 (ko) 신규 화합물 및 이를 포함하는 약학 조성물
JPH1081622A (ja) 新規な一酸化窒素合成酵素阻害剤